New drug targets Hard-to-Treat cancers in early trial

NCT ID NCT05485974

Ongoing Disease control Sponsor: HUYABIO International, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial is testing a new drug called HBI-2438 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About 44 adults who have tried other treatments without success are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HBI-2438 (a KRAS G12C inhibitor)
What this could lead to: If it works, this could point toward a new treatment option for people with certain cancers that have a specific genetic mutation (KRAS G12C).
What could go wrong: This is a very early (Phase 1) trial with only 44 participants, so it is primarily testing safety and dosing. It is too soon to know if the drug will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer colon carcinoma colonic neoplasm colorectal cancer colorectal neoplasm lung cancer lung neoplasm malignant pancreatic neoplasm neoplasm non-small cell lung carcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER CANCER OF PANCREAS COLON CANCER COLORECTAL CANCER LUNG CANCER NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC

Kansas City, Missouri, 64114, United States
BRCR Medical Center

Plantation, Florida, 33322, United States
California Cancer Associates for Research and Excellence, Inc. (cCare)

Encinitas, California, 92024, United States
California Cancer Associates for Research and Excellence, Inc. (cCare)

San Marcos, California, 92069, United States
Gabrail Cancer Center

Canton, Ohio, 44718, United States
Innovative Clinical Research Institute (ICRI)

Whittier, California, 90603, United States
Michigan Center of Medical Research

Farmington Hills, Michigan, 48334, United States
Pan American Center for Oncology Trials (PanOncology Trials)

Rio Piedras, Puerto Rico, 00935, Puerto Rico
Sarcoma Oncology

Santa Monica, California, 90403, United States
The Oncology Institute of Hope and Innovation

Glendale, California, 91204, United States
The Oncology Institute of Hope and Innovation

Long Beach, California, 90805, United States
The Oncology Institute of Hope and Innovation

Pasadena, California, 91105, United States
The Oncology Institute of Hope and Innovation

Santa Ana, California, 92705, United States
The Oncology Institute of Hope and Innovation

Whittier, California, 90603, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.